Nektar Therapeutics (NKTR) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Nektar Therapeutics’s revenue went from $165M in fiscal 2016 to $55M in fiscal 2025, a decline of about 11.5% a year.
Net income in fiscal 2025 was -$164M, a net margin of -297.1%; the best year in this period was 2018 with $681M.
Over the twelve months to September 30, 2026, revenue was $52M and net income -$177M.
Free cash flow was -$209M in fiscal 2025 and positive in 1 of the 10 years shown.
The diluted share count rose 81% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $52M | $55M | $98M | $90M | $92M | $102M | $153M | $115M | $1.2B | $308M | $165M |
| Gross profit | — | $55M | $68M | $56M | $70M | $77M | $133M | $93M | $1.2B | $277M | $135M |
| Operating income | -$167M | -$140M | -$105M | -$264M | -$376M | -$446M | -$425M | -$440M | $688M | -$60M | -$113M |
| Net income | -$177M | -$164M | -$119M | -$276M | -$368M | -$524M | -$444M | -$441M | $681M | -$97M | -$154M |
| EPS (diluted) | $-5.25 | $-4.87 | $-4.34 | $-10.87 | $-14.77 | $-21.45 | $-18.67 | $-18.90 | $28.35 | $-4.65 | $-8.25 |
| R&D | $149M | $117M | $121M | $114M | $218M | $400M | $409M | $435M | $400M | $268M | $204M |
| Revenue growth | — | −43.9% | +9.2% | −2.1% | −9.7% | −33.4% | +33.4% | −90.4% | +287.8% | +86.0% | −28.3% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$257M | -$209M | -$176M | -$193M | -$304M | -$413M | -$313M | -$329M | $718M | -$80M | -$117M |
| Capital spending | -$528000 | -$171000 | -$1M | -$865000 | -$6M | -$15M | -$7M | -$26M | -$14M | -$10M | -$6M |
| Free cash flow | -$257M | -$209M | -$177M | -$193M | -$310M | -$428M | -$321M | -$355M | $704M | -$90M | -$123M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | $0 | $3M | $0 | — | — | — | — | — | — | — |
| Stock-based pay | $13M | $13M | $22M | $33M | $57M | $95M | $94M | $100M | $88M | $37M | $26M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $246M | $255M | $304M | $505M | $734M | $1.1B | $1.3B | $1.3B | $296M | $60M |
| Debt | — | $86M | $103M | $118M | $131M | $143M | $150M | $405M | $250M | $250M | $250M |
| Equity | — | $90M | $61M | $131M | $367M | $680M | $1.1B | $1.4B | $1.7B | $88M | $88M |
| Total assets | — | $280M | $304M | $398M | $711M | $1.1B | $1.5B | $2.0B | $2.2B | $509M | $569M |
| Shares (diluted) | — | 34M | 27M | 25M | 25M | 24M | 24M | 23M | 24M | 21M | 19M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | 100.0% | 68.8% | 62.5% | 76.5% | 75.6% | 87.3% | 81.3% | 98.0% | 90.1% | 81.7% |
| Operating margin | -319.8% | -253.7% | -106.9% | -292.6% | -408.6% | -437.8% | -278.0% | -383.9% | 57.6% | -19.4% | -68.2% |
| Net margin | -339.7% | -297.1% | -120.9% | -306.3% | -400.0% | -514.0% | -290.6% | -384.5% | 57.1% | -31.4% | -92.8% |
| FCF margin | -493.4% | -377.8% | -180.0% | -214.7% | -336.4% | -419.7% | -209.6% | -309.7% | 59.0% | -29.3% | -74.6% |
| ROIC | — | -79.7% | -64.3% | -105.9% | -59.7% | -42.8% | -27.4% | -19.2% | 34.9% | -14.0% | -26.4% |
| ROE | — | -182.7% | -195.9% | -210.8% | -100.4% | -77.1% | -41.3% | -31.4% | 39.7% | -110.1% | -174.2% |
Frequently asked questions
What is Nektar Therapeutics’s annual revenue?
$55M in fiscal 2025 and $52M over the twelve months to September 30, 2026.
How much profit does Nektar Therapeutics make?
Net income was -$164M in fiscal 2025 (net margin -297.1%).
Is Nektar Therapeutics’s revenue growing?
No: revenue fell 43.9% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.